PhaseBio Pharmaceuticals, Inc

3:30 PM - 3:45 PM, Tuesday, June 4, 2019 ・ Theater 3
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary disorders. PhaseBio is leveraging its proprietary elastin-like polypeptide (“ELP”) technology platform to develop therapies with the potential for less-frequent dosing and improved pharmacokinetics. PhaseBio’s product PB1046 is based on the ELP platform and is a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension. PhaseBio is located in Malvern, PA and San Diego, CA. For more information, please visit www.phasebio.com.
Ticker:
PHAS
Exchange:
NASDAQ
Company Type:
Company Website:
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
Not Provided.
Main Therapeutic Focus:
Lead Product in Development:
PB2452 and PB1046
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.
Speaker
photo
Chief Medical Officer
PhaseBio Pharmaceuticals, Inc.